查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1614333

進行性肌肉骨化症市場：按產品、給藥途徑和最終用戶分類 - 全球預測 2025-2030

Fibrodysplasia Ossificans Progressiva Market by Offering (Drug Type, Treatment), Route of Administration (Oral, Parenteral, Topical), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，進行性肌肉骨化症市場價值為4.7046億美元，預計到2024年將達到4.9459億美元，複合年成長率為5.30%，到2030年預計將達到6.7565億美元。

進行性肌肉骨化症(FOP) 是一種極為罕見的遺傳性疾病，會導致軟組織逐漸骨化，嚴重限制身體活動能力並引起對身體功能至關重要的併發症。 FOP 的市場範圍雖然因其稀有性而高度專業化，但由於其對患者生活品質的重大影響，從醫學研究和創新的角度來看至關重要。目前缺乏有效的治療方案，凸顯了開發預防藥物和治療方法的必要性，凸顯了人道主義和經濟獎勵。應用範圍從開發新藥、基因治療和骨生物學研究到針對運動功能障礙的輔助技術和義肢。主要最終用戶是醫療提供者、研究機構和製藥公司，初級和二級研究針對義肢假體製造商。

主要市場統計
基準年[2023] 47046萬美元
預計年份 [2024] 4.9459 億美元
預測年份 [2030] 67565萬美元
複合年成長率（%） 5.30%

政府和私人資金的增加、遺傳學的進步以及醫療專業人員意識的提高推動了市場的成長，這推動了生物技術公司和學術機構之間的合作。利用先進的 CRISPR 技術進行基因編輯和開發針對異位性骨化症特定途徑的生技藥品存在潛在的機會。抓住這些機會的建議包括建立策略夥伴關係關係以共用資源以及投資早期生物製藥企業。然而，研究和臨床測試的高成本和時間、使研究可行性複雜化的患者群體小以及監管障礙等限制仍然是巨大的挑戰。

創新前景包括探索新的分子途徑、利用人工智慧和機器學習來改進診斷工具，以及利用患者主導的資料集集來增強個人化醫療方法。該市場的特點是動態和利基性質，需要敏捷性和持續的研發投資。將創新努力與以患者為中心的護理模式相結合，利用新技術，並在相關人員之間培育協作生態系統，將有助於我們的業務隨著罕見疾病治療解決方案的發展而同步成長。

市場動態：揭示快速進行性肌肉骨化症不良進展市場的關鍵市場洞察

供需的動態交互作用正在改變進行性肌肉骨化症市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 進行性肌肉骨化症盛行率增加
    • 提高醫療專業人員和公眾對罕見疾病和遺傳疾病的認知
  • 市場限制因素
    • 開發進行進行性肌肉骨化症治療方法的成本高昂
  • 市場機會
    • 活性化研發活動，開發進行進行性肌肉骨化症的新治療方法
    • 政府資助的可用性和罕見疾病的批准
  • 市場問題
    • 對進行性肌肉骨化症的認知較低

波特的五力：導航進行性肌肉骨化症市場的策略工具

波特的五力架構是了解進行進行性肌肉骨化症市場競爭格局的關鍵工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解對進行性肌肉骨化症市場的外部影響

外部宏觀環境因素在塑造進行進行性肌肉骨化症市場的績效動態發揮關鍵作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解進行進行性肌肉骨化症市場的競爭格局

對進行性肌肉骨化症市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣：進行性肌肉骨化症市場供應商的績效評估

FPNV 定位矩陣是評估進行進行性肌肉骨化症市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：在進行性肌肉骨化症市場中製定成功之路

對於旨在加強其在全球市場的影響力的公司來說，對進行性肌肉骨化症市場進行策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、主要產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 進行性肌肉骨化症的發生率增加
      • 提高醫療專業人員和公眾對罕見疾病和遺傳疾病的認知
    • 抑制因素
      • 進行進行性肌肉骨化症治療的開發成本很高
    • 機會
      • 增加研發活動以開發新治療方法
      • 政府對罕見疾病的資助和核准
    • 任務
      • 對進行性肌肉骨化症的認知較低
  • 市場區隔分析
    • 產品：增加對 parovalotene 的需求，以抑制 FOP異位性骨化症的進展
    • 最終使用者：進行性肌肉骨化症藥物經常在醫院用於 FOP 的診斷、治療和持續管理。
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章進行性肌肉骨化症市場：依產品分類

  • 介紹
  • 藥物類型
    • 抗發炎藥
    • 雙磷酸鹽
    • 皮質類固醇
    • 帕瓦洛汀
  • 治療
    • 藥物治療
    • 職能治療
    • 外科手術

第7章進行性肌肉骨化症市場：依給藥途徑

  • 介紹
  • 口服
  • 胃腸外的
  • 局部的

第 8 章進行性肌肉骨化症市場：依最終用戶

  • 介紹
  • 醫院
  • 研究所
  • 專科診所

第9章北美和南美的進行性肌肉骨化症市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區進行性肌肉骨化症市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的進行性肌肉骨化症市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准Ipsen 治療進行進行性肌肉骨化症
  • 戰略分析和建議

公司名單

  • Abbvie Inc.
  • Accord Healthcare, Inc
  • Amgen Inc.
  • BioCryst Pharmaceuticals, Inc.
  • bioMerieux SA
  • Blueprint Medicines Corporation
  • Boehringer Ingelheim International GmbH
  • Daiichi Sankyo Company, Limited
  • Incyte Corporation
  • Ipsen Pharma
  • Merck & Co Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-9E71DF483BA8

The Fibrodysplasia Ossificans Progressiva Market was valued at USD 470.46 million in 2023, expected to reach USD 494.59 million in 2024, and is projected to grow at a CAGR of 5.30%, to USD 675.65 million by 2030.

Fibrodysplasia Ossificans Progressiva (FOP) is an ultra-rare, genetic disorder that causes soft tissues to progressively ossify, severely limiting physical mobility and leading to complications in essential bodily functions. The market scope for FOP is highly specialized, given its rarity, but it is critical in terms of medical research and innovation due to the significant impact on patient quality of life. The necessity of developing preventatives and therapeutics is underscored by the lack of effective treatment options currently available, emphasizing both humanitarian and financial incentives. Applications range from novel drug development, gene therapy, and bone biology research to assistive technology and prosthetics that cater specifically to impaired mobility. In terms of end-use, the primary focus is on healthcare providers, research organizations, and pharmaceutical companies, with a secondary market in adaptive equipment manufacturers.

KEY MARKET STATISTICS
Base Year [2023] USD 470.46 million
Estimated Year [2024] USD 494.59 million
Forecast Year [2030] USD 675.65 million
CAGR (%) 5.30%

Market growth is driven by increasing government and private funding, advancements in genetics, and rising awareness among healthcare professionals, which stroke collaborations across biotech firms and academic institutions. Potential opportunities exist in leveraging advanced CRISPR technology for gene editing and developing biologics that target the specific pathways involved in heterotopic ossification. Recommendations to seize these opportunities include forming strategic partnerships for resource sharing and investing in early-stage biopharmaceutical ventures. However, limitations like the high cost and time associated with research and clinical trials, small patient populations complicating study feasibility, and regulatory hurdles remain formidable challenges.

Innovation prospects include exploring new molecular pathways, improving diagnostic tools with AI and machine learning, and using patient-driven datasets to enhance personalized medicine approaches. The market is characterized by its dynamic, niche nature-demanding agility and sustained R&D investment. Business growth can be maximized by aligning innovation efforts with patient-centric care models, leveraging emerging technologies, and fostering a collaborative ecosystem among stakeholders, thus keeping pace with the evolving landscape of rare disease treatment solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Fibrodysplasia Ossificans Progressiva Market

The Fibrodysplasia Ossificans Progressiva Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing incidence of fibrodysplasia ossificans progressiva diseases
    • Rising awareness among healthcare professionals and the public for rare and genetic diseases
  • Market Restraints
    • High cost of development of fibrodysplasia ossificans progressiva treatment
  • Market Opportunities
    • Rising research & development activities to develop novel fibrodysplasia ossificans progressiva treatments
    • Availability of government funding and approvals for rare diseases
  • Market Challenges
    • Limited awareness for the fibrodysplasia ossificans progressiva

Porter's Five Forces: A Strategic Tool for Navigating the Fibrodysplasia Ossificans Progressiva Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Fibrodysplasia Ossificans Progressiva Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Fibrodysplasia Ossificans Progressiva Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Fibrodysplasia Ossificans Progressiva Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Fibrodysplasia Ossificans Progressiva Market

A detailed market share analysis in the Fibrodysplasia Ossificans Progressiva Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Fibrodysplasia Ossificans Progressiva Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Fibrodysplasia Ossificans Progressiva Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Fibrodysplasia Ossificans Progressiva Market

A strategic analysis of the Fibrodysplasia Ossificans Progressiva Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Fibrodysplasia Ossificans Progressiva Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Accord Healthcare, Inc, Amgen Inc., BioCryst Pharmaceuticals, Inc., bioMerieux S.A., Blueprint Medicines Corporation, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, Incyte Corporation, Ipsen Pharma, Merck & Co Inc., Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Fibrodysplasia Ossificans Progressiva Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Offering, market is studied across Drug Type and Treatment. The Drug Type is further studied across Anti-inflammatory Medications, Bisphosphonates, Corticosteroids, and Palovarotene. The Treatment is further studied across Medication, Occupational Therapy, and Surgery.
  • Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
  • Based on End-User, market is studied across Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidence of fibrodysplasia ossificans progressiva diseases
      • 5.1.1.2. Rising awareness among healthcare professionals and the public for rare and genetic diseases
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of development of fibrodysplasia ossificans progressiva treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising research & development activities to develop novel fibrodysplasia ossificans progressiva treatments
      • 5.1.3.2. Availability of government funding and approvals for rare diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness for the fibrodysplasia ossificans progressiva
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Rising need for palovarotene for reducing the progression of heterotopic ossification in FOP
    • 5.2.2. End-User: High usage of fibrodysplasia ossificans progressiva drugs in hospitals for diagnosis, treatment, and ongoing management of FOP
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Fibrodysplasia Ossificans Progressiva Market, by Offering

  • 6.1. Introduction
  • 6.2. Drug Type
    • 6.2.1. Anti-inflammatory Medications
    • 6.2.2. Bisphosphonates
    • 6.2.3. Corticosteroids
    • 6.2.4. Palovarotene
  • 6.3. Treatment
    • 6.3.1. Medication
    • 6.3.2. Occupational Therapy
    • 6.3.3. Surgery

7. Fibrodysplasia Ossificans Progressiva Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral
  • 7.4. Topical

8. Fibrodysplasia Ossificans Progressiva Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Research Institutes
  • 8.4. Specialty Clinics

9. Americas Fibrodysplasia Ossificans Progressiva Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Fibrodysplasia Ossificans Progressiva Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Fibrodysplasia Ossificans Progressiva Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Approves Ipsen Fibrodysplasia Ossificans Progressiva Treatment
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie Inc.
  • 2. Accord Healthcare, Inc
  • 3. Amgen Inc.
  • 4. BioCryst Pharmaceuticals, Inc.
  • 5. bioMerieux S.A.
  • 6. Blueprint Medicines Corporation
  • 7. Boehringer Ingelheim International GmbH
  • 8. Daiichi Sankyo Company, Limited
  • 9. Incyte Corporation
  • 10. Ipsen Pharma
  • 11. Merck & Co Inc.
  • 12. Novartis AG
  • 13. Pfizer, Inc.
  • 14. Regeneron Pharmaceuticals, Inc.
  • 15. Sun Pharmaceutical Industries Ltd.
  • 16. Teva Pharmaceuticals Industries Ltd.
  • 17. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET RESEARCH PROCESS
  • FIGURE 2. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET DYNAMICS
  • TABLE 7. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY PALOVAROTENE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OCCUPATIONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 237. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET, FPNV POSITIONING MATRIX, 2023